Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21ClF2N4O |
| Molecular Weight | 394.846 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN=C(CNCC2(F)CCN(CC2)C(=O)C3=CC=C(F)C(Cl)=C3)N=C1
InChI
InChIKey=WAAXKNFGOFTGLP-UHFFFAOYSA-N
InChI=1S/C19H21ClF2N4O/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14/h2-3,8-10,23H,4-7,11-12H2,1H3
F-15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT(1A) receptors. In signal transduction, electrophysiological and neurochemical tests, F-15599 preferentially activates post-synaptic 5-HT(1A)Rs in rat frontal cortex. Such a profile may translate to an improved profile of therapeutic activity for mood disorders. [(18)F]F-15599 is a radiofluorinated agonist presenting interesting characteristics for probing in vitro and in vivo the high-affinity states of the 5-HT(1A) receptors. The Rett Syndrome Research Trust awarded a grant to Neurolixis to advance F-15599 to clinical development.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. | 2007 Oct 4 |
|
| Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. | 2009 Jan |
|
| Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. | 2010 Aug |
|
| [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. | 2010 Mar |
|
| F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. | 2010 Nov |
|
| F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. | 2010 Sep |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
410613
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/14/1242
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
83481Y1YCX
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY | |||
|
635323-95-4
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY | |||
|
SUB195709
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY | |||
|
DTXSID901029377
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY | |||
|
100000181855
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY | |||
|
F-15,599
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY | |||
|
11741361
Created by
admin on Sat Dec 16 11:05:09 GMT 2023 , Edited by admin on Sat Dec 16 11:05:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
